Myriad to Co-market Sividon Breast Cancer Test | GenomeWeb

NEW YORK (GenomeWeb News) – Myriad Genetics GmbH and Sividon Diagnostics today announced a deal granting Myriad the exclusive rights to co-market Sividon's EndoPredict prognostic test kit for breast cancer patients outside the US.

The deal leverages Myriad's 45-person international commercial team and will "significantly increase" the number of medical specialists and sales professionals supporting EndoPredict, according to the companies.

Myriad Genetics GmbH is the international subsidiary of Myriad Genetics and is based in Zurich.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: role for epigenetic in neuronal excitability, and more.

The new Office of Research Integrity director is grappling with complaints from her staff, according to ScienceInsider.

Italian researchers link SNPs in the PDSS2 gene to coffee consumption in a new paper.

A gene-editing ban has been interpreted to include mitochondrial transfer, Technology Review reports.